Table 4

Descriptive analysis of resistance patterns in the recommendations grouped by syndrome (n=251)

CAP,
n (%)
UTI,
n (%)
AOM,
n (%)
RHI,
n (%)
PHA,
n (%)
Recommendations considering resistance patterns
 Antibiotic used as an alternative because of high resistance rate14 (19.2)9 (14.3)5 (11.9)3 (7.7)1 (2.9)
 Antibiotic not indicated because of high resistance rate2 (2.7)6 (9.5)1 (2.4)3 (7.7)5 (14.7)
 Resistance risk12 (16.4)7 (11.1)4 (9.5)3 (7.7)_
 Resistance threshold_9 (14.3)_2 (5.1)2 (5.9)
 Resistance AB_5 (7.9%)___
 Resistance dosage8 (11.0)_7 (16.7)8 (20.5)_
 Atypical pathogens19 (26.0)___1 (2.9)
 MRSA risk7 (9.6)____
 MDR risk1 (1.4)5 (7.9)1 (2.4)__
 PRSP risk6 (8.2)_6 (14.3)5 (12.8)_
Pseudomonas risk14 (19.2)____
 Beta-lactamase risk8 (11.0)_11 (26.2)7 (17.9)_
Discrete resistance patterns mentioned in recommendations
 Total106774
Median
n
(%)
 
3
(30.0)
 
2
(33.3)
 
2
(28.6)
 
3.5
(50.0)
 
1
(25.0)
IQR
n
(%)
 
2–3
(20–30)
 
2–5
(33.3–83.3)
 
1.3–3
(17.9–42.9)
 
1.7–4
(21.4–57.1)
 
1–1
(25–25)
  • AOM, acute otitis media; Atypical pathogens, risk of atypical pathogens; CAP, community acquired pneumonia; MDR risk, risk of multidrug resistant strains; MRSA risk, risk of meticillin-resistant Staphylococcus aureus; PHA, pharyngitis; PRSP risk, risk of penicillin resistant Streptococcus pneumonia; Pseudomonas risk, risk of Pseudomonas aeruginosa; Resistance AB, antibiotic used if first-line AB is resistant; Resistance dosage, antibiotic used at high dosage if there is a risk of resistant strains; Resistance risk, antibiotic used only if there is a risk of increasing resistance (eg, recent use of critical AB during past months); Resistance threshold, antibiotic used only under a certain threshold of resistance; RHI, rhinosinusitis; UTI, urinary tract infection; beta-lactamase risk, risk of strains producing beta-lactamase.